Loxo@Lilly

Loxo@Lilly is the integrated oncology division of Eli Lilly, formed after Eli Lilly's acquisition of Loxo Oncology in January 2019 for $8 billion. This acquisition marked Eli Lilly's largest in its history, enhancing its capabilities in cancer treatment. Loxo Oncology, founded in 2013, focuses on developing targeted cancer therapies for genetically-defined patient populations. The company specializes in medicines for patients with genomically defined cancers, particularly those reliant on specific gene abnormalities. Its product pipeline includes advanced treatments, such as LOXO-292, which targets tumors with rare RET gene abnormalities. Following the merger, Loxo operates within Eli Lilly's oncology division, continuing its mission to innovate in cancer therapy.